Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy of a single dose of baloxavir marboxil in the prevention of influenza virus infection

Trial Profile

A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy of a single dose of baloxavir marboxil in the prevention of influenza virus infection

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Baloxavir-marboxil (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Shionogi
  • Most Recent Events

    • 08 Nov 2018 Status changed from planning to recruiting.
    • 20 Sep 2018 New trial record
    • 05 Sep 2018 According to a Shionogi media release, this study will be conducted in the 2018/2019 flu season.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top